* Prothena Corporation PLC PRTA.OQ reported a quarterly
adjusted
loss of $1.10 per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of 38 cents. The mean expectation of eight analysts for the
quarter was for a loss of $1.18 per share. Wall Street expected
results to range from $-1.28 to $-1.03 per share.
* Revenue fell 98.9% to $970.00 thousand from a year ago;
analysts
expected $1.23 million.
* Prothena Corporation PLC's reported EPS for the quarter
was a
loss of $1.10.
* The company reported a quarterly loss of $59 million.
* Prothena Corporation PLC shares had risen by 3.8% this
quarter and lost 52.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Prothena
Corporation PLC is $62.00
This summary was machine generated from LSEG data November 13 at
02:24 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.18 -1.10 Beat
Jun. 30 2024 -1.05 1.22 Beat
Mar. 31 2024 -1.20 -1.34 Missed
Dec. 31 2023 -1.22 -1.26 Missed